• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

《2024年乳腺癌最新进展 第二部分 - 早期乳腺癌患者》

Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.

作者信息

Janni Wolfgang, Kolberg Hans-Christian, Hartkopf Andreas D, Fehm Tanja N, Welslau Manfred, Müller Volkmar, Schütz Florian, Fasching Peter A, Jackisch Christian, Marme Frederik, Hörner Manuel, Keller Katharina, Goossens Chloë, Belleville Erik, Untch Michael, Thill Marc, Tesch Hans, Ditsch Nina, Lux Michael P, Banys-Paluchowski Maggie, Wöckel Achim, Harbeck Nadia, Stickeler Elmar, Bartsch Rupert, Aktas Bahriye, Schneeweiss Andreas, Ettl Johannes, Taran Florin-Andrei, Lüftner Diana, Würstlein Rachel, Radosa Julia C

机构信息

Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany.

Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.

出版信息

Geburtshilfe Frauenheilkd. 2025 May 15;85(5):493-506. doi: 10.1055/a-2533-2783. eCollection 2025 May.

DOI:10.1055/a-2533-2783
PMID:40386499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12081099/
Abstract

This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.

摘要

本综述总结了早期乳腺癌患者治疗的最新进展。大多数具有临床相关性的变化是由于使用免疫检查点抑制剂治疗三阴性乳腺癌（TNBC）患者以及使用CDK4/6抑制剂治疗激素受体阳性、HER2阴性（HRpos/HER2neg）且复发风险高的肿瘤患者所致。近期研究呈现出越来越多随访时间长的数据，并整合了转化分析以评估新的生物标志物，如循环肿瘤DNA（ctDNA）。这篇综述文章总结了近几个月发表的最新进展，并将研究结果置于相应背景中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/8a8a12c8e9f8/10-1055-a-2533-2783-igfde09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/f4624a2972c6/10-1055-a-2533-2783-igf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/c46616277531/10-1055-a-2533-2783-igf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/fc46cbb638df/10-1055-a-2533-2783-igf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/9a3b61b9f3f0/10-1055-a-2533-2783-igf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/bf7d54fbf81f/10-1055-a-2533-2783-igf05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/3f8aafd968fa/10-1055-a-2533-2783-igf06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/cc12add3ec1f/10-1055-a-2533-2783-igf07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/a5a0979581e9/10-1055-a-2533-2783-igf08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/0492bdf104f6/10-1055-a-2533-2783-igf09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/bf8ec0d28e57/10-1055-a-2533-2783-igfde01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/1b87f0092cb7/10-1055-a-2533-2783-igfde02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/a52c82832d9e/10-1055-a-2533-2783-igfde03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/3a7243e13afc/10-1055-a-2533-2783-igfde04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/56a825b23e18/10-1055-a-2533-2783-igfde05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/1ee7cb8c358f/10-1055-a-2533-2783-igfde06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/37282f454192/10-1055-a-2533-2783-igfde07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/2257f1c7f28b/10-1055-a-2533-2783-igfde08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/8a8a12c8e9f8/10-1055-a-2533-2783-igfde09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/f4624a2972c6/10-1055-a-2533-2783-igf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/c46616277531/10-1055-a-2533-2783-igf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/fc46cbb638df/10-1055-a-2533-2783-igf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/9a3b61b9f3f0/10-1055-a-2533-2783-igf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/bf7d54fbf81f/10-1055-a-2533-2783-igf05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/3f8aafd968fa/10-1055-a-2533-2783-igf06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/cc12add3ec1f/10-1055-a-2533-2783-igf07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/a5a0979581e9/10-1055-a-2533-2783-igf08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/0492bdf104f6/10-1055-a-2533-2783-igf09.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/bf8ec0d28e57/10-1055-a-2533-2783-igfde01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/1b87f0092cb7/10-1055-a-2533-2783-igfde02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/a52c82832d9e/10-1055-a-2533-2783-igfde03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/3a7243e13afc/10-1055-a-2533-2783-igfde04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/56a825b23e18/10-1055-a-2533-2783-igfde05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/1ee7cb8c358f/10-1055-a-2533-2783-igfde06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/37282f454192/10-1055-a-2533-2783-igfde07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/2257f1c7f28b/10-1055-a-2533-2783-igfde08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0988/12081099/8a8a12c8e9f8/10-1055-a-2533-2783-igfde09.jpg

相似文献

1
Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.《2024年乳腺癌最新进展 第二部分 - 早期乳腺癌患者》
Geburtshilfe Frauenheilkd. 2025 May 15;85(5):493-506. doi: 10.1055/a-2533-2783. eCollection 2025 May.
2
Update Breast Cancer 2022 Part 6 - Advanced-Stage Breast Cancer.《2022年乳腺癌最新进展 第6部分 - 晚期乳腺癌》
Geburtshilfe Frauenheilkd. 2023 Mar 9;83(3):299-309. doi: 10.1055/a-2018-9184. eCollection 2023 Mar.
3
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk.芳香化酶抑制剂、他莫昔芬及卵巢功能抑制在复发风险增加的绝经前激素受体阳性、HER2阴性早期乳腺癌患者中的真实世界应用情况
Breast. 2025 Jun;81:104458. doi: 10.1016/j.breast.2025.104458. Epub 2025 Mar 22.
4
Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low.三阴性乳腺癌的临床和生物学异质性揭示了 HER2 低表达的不可忽视作用。
Breast Cancer Res. 2023 Mar 30;25(1):34. doi: 10.1186/s13058-023-01639-y.
5
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.高危早期 HER2 阴性乳腺癌患者接受新辅助化疗时循环肿瘤 DNA 的临床意义和生物学特性。
Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008. Epub 2023 May 4.
6
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.TROPION-Breast04：一项关于新辅助达妥昔单抗（Dato-DXd）联合度伐利尤单抗治疗，随后辅助使用度伐利尤单抗与初治早期三阴性或激素受体低表达/人表皮生长因子受体2阴性乳腺癌患者的标准治疗方案对比的随机III期研究。
Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177/17588359251316176. eCollection 2025.
7
Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.循环肿瘤 DNA 作为一种新型生物标志物优化三阴性乳腺癌的治疗。
Clin Breast Cancer. 2023 Jun;23(4):339-349. doi: 10.1016/j.clbc.2023.02.012. Epub 2023 Mar 2.
8
Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer.《2022年乳腺癌最新进展 第二部分 - 晚期乳腺癌》
Geburtshilfe Frauenheilkd. 2022 Jun 3;82(6):590-600. doi: 10.1055/a-1811-6148. eCollection 2022 Jun.
9
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.新辅助化疗后循环肿瘤 DNA 和循环肿瘤细胞与三阴性乳腺癌患者疾病复发的关系：BRE12-158 随机临床试验的预先计划的二次分析。
JAMA Oncol. 2020 Sep 1;6(9):1410-1415. doi: 10.1001/jamaoncol.2020.2295.
10
Role of circulating tumor DNA in early-stage triple-negative breast cancer: a systematic review and meta-analysis.循环肿瘤DNA在早期三阴性乳腺癌中的作用：一项系统评价和荟萃分析。
Breast Cancer Res. 2025 Mar 12;27(1):38. doi: 10.1186/s13058-025-01986-y.

本文引用的文献

1
Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.欧洲血统人群中多基因评分分布差异：对乳腺癌风险预测的影响
Breast Cancer Res. 2024 Dec 29;26(1):189. doi: 10.1186/s13058-024-01947-x.
2
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌的总生存期。
N Engl J Med. 2024 Nov 28;391(21):1981-1991. doi: 10.1056/NEJMoa2409932. Epub 2024 Sep 15.
3
Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
绝经后 HR 阳性/HER2 阴性乳腺癌患者接受来曲唑一线治疗，当前辅助内分泌治疗试验 NATALEE 和 monarchE 的选择标准对预后的影响。
Eur J Cancer. 2024 Sep;209:114239. doi: 10.1016/j.ejca.2024.114239. Epub 2024 Jul 21.
4
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer.HER2阴性晚期乳腺癌患者生殖系及肿瘤中的易感基因突变
NPJ Breast Cancer. 2024 Jul 13;10(1):57. doi: 10.1038/s41523-024-00667-x.
5
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study.新辅助帕博利珠单抗联合化疗/辅助帕博利珠单抗治疗早期三阴性乳腺癌：来自随机 KEYNOTE-522 研究的生活质量结果。
J Natl Cancer Inst. 2024 Oct 1;116(10):1654-1663. doi: 10.1093/jnci/djae129.
6
Ribociclib plus Endocrine Therapy in Early Breast Cancer.来曲唑联合内分泌治疗早期乳腺癌。
N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.
7
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?他莫昔芬剂量降级：降低不良反应的有效策略？
Drugs. 2024 Apr;84(4):385-401. doi: 10.1007/s40265-024-02010-x. Epub 2024 Mar 14.
8
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.帕博利珠单抗治疗早期三阴性乳腺癌时基于残留癌负荷的无事件生存期：KEYNOTE-522研究的探索性分析
Ann Oncol. 2024 May;35(5):429-436. doi: 10.1016/j.annonc.2024.02.002. Epub 2024 Feb 17.
9
Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study.来曲唑一线治疗早期乳腺癌患者在常规临床护理中的长期随访及安全性——PreFace研究
Geburtshilfe Frauenheilkd. 2024 Feb 8;84(2):185-195. doi: 10.1055/a-2238-3153. eCollection 2024 Feb.
10
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.基线雌二醇血清浓度对阿那曲唑预防高危绝经后妇女乳腺癌疗效的影响：IBIS-II 预防试验的病例对照研究。
Lancet Oncol. 2024 Jan;25(1):108-116. doi: 10.1016/S1470-2045(23)00578-8. Epub 2023 Dec 6.